Chief Executive Officer Barry Quart said the company’s rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results